Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Official record

Identifier

NCT05327465

Recruiting locations

country

United States

Interventions studied

Aerobic and resistance exerciseUsual Care

Lead sponsor

Dana-Farber Cancer Institute

Target enrolment

62 participants

Study type

INTERVENTIONAL

Phase

Not applicable

Status

Recruiting

First posted

Apr 14, 2022

Last updated on the registry

Jul 29, 2026

Age

18 Years

Sex

MALE

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* Patients must meet all criteria to be eligible, including travel to Dana-Farber Cancer Institute (DFCI) to collect research data to address the study question.
* Over 18 years old; children under the age of 18 will be excluded due to the rarity of the disease
* Histologically diagnosed of localized or metastatic prostate cancer
* Have been receiving androgen deprivation therapy (ADT) (i.e., luteinizing hormone-releasing hormone \[LHRH\] agonist/antagonist and/or androgen receptor \[AR\] agonist/antagonist) for at least one month with a plan to continue ADT for at least 4 months at the time of recruitment
* Self-identify as Black
* Medically cleared to participate in exercise by their referred physician or a certified clinical exercise physiologist
* Are without medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases
* Speak English and/or Spanish
* Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week
* Willing to travel to DFCI for necessary data collection
* Ability to communicate and complete written forms in English and/or Spanish

Exclusion Criteria:

* Are not receiving ADT (i.e., LHRH agonist/antagonist and/or AR agonist/antagonist)
* Pre-existing medical conditions such as uncontrolled cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise
* Are not English or Spanish speaking
* Patients with secondary diagnosis (with the exception of basal cell carcinoma)
* Participate in more than 60 minutes of moderate or vigorous structured exercise/week
* Unable to travel to DFCI for necessary data collection
* May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.